Trial reportPediatric blood & cancer2012
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Trial report in Pediatric blood & cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Targeting notch signaling to restore neural development and behavior in mouse models of ASD.Nature communications · 2026Article
- NOTCH Signaling in Osteosarcoma.Current issues in molecular biology · 2023Review
- Unlocking the Secrets of Cancer Stem Cells with γ-Secretase Inhibitors: A Novel Anticancer Strategy.Molecules (Basel, Switzerland) · 2021Review
- FAK Signaling in Rhabdomyosarcoma.International journal of molecular sciences · 2020Review
- Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.International journal of molecular sciences · 2020Review
- Targeting the Notch and TGF-β signaling pathways to prevent retinal fibrosisTheranostics · 2020Article
- Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.BMC cancer · 2019Article
- The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.Oncotarget · 2017Article
- Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Nature reviews. Endocrinology · 2017Review
- A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.Leukemia · 2016Review
- Article
- Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia?Current oncology (Toronto, Ont.) · 2016Review
- Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.PloS one · 2015Article
- Translational biology of osteosarcoma.Nature reviews. Cancer · 2014Review
- Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Pediatric blood & cancer · 2014Article
- Molecular profiling of childhood cancer: Biomarkers and novel therapies.BBA clinical · 2014Review
- Therapeutic modulation of Notch signalling--are we there yet?Nature reviews. Drug discovery · 2014Review
- The emerging roles of Notch signaling in leukemia and stem cells.Biomarker research · 2013Article
- Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Notch signaling in skeletal health and disease.European journal of endocrinology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
RO4929097 is a potent and selective inhibitor of γ-secretase and as a result is able to inhibit Notch pathway signaling. The activity of RO4929097 was evaluated against the in vivo panels of the Pediatric Preclinical Testing Program (PPTP). RO4929097 induced significant differences in event-free survival (EFS) distribution compared to control in 6 of 26 (23%) of the evaluable solid tumor xenografts and in 0 of 8 (0%) of the evaluable ALL xenografts. The most consistent tumor growth delay effects were noted in the osteosarcoma panel. RO4929097 at the dose and schedule evaluated demonstrated little antitumor activity against childhood cancer xenografts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.